Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lercanidipine

Drug Profile

Lercanidipine

Alternative Names: Cardiovasc; Carmen; Corifeo; Lercadip; Lercapdip; Lerdip; Lerez; Lerka; Lerzam; R 75; REC 152375; TJN 324; Vasodip; Zanedip; Zanidip

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Recordati
  • Developer A.R. Kamm Associates; Algorithm; Andromaco; Dexcel-Pharma; Digital Gene Technologies; Elmor; Fako Ilaclari; Forest Laboratories; Fournier Pharma Inc; Gador; Grunenthal; Himont Pharmaceutical; Laboratoires Fournier; Laboratorios Sanfer; LG Chem; Meda; Orient Europharma; Recordati; Robapharm; Solvay; UCB; Zuoz Pharma
  • Class Antihypertensives; Dihydropyridines; Ischaemic heart disorder therapies; Small molecules
  • Mechanism of Action Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 08 May 2020 Allergan has been acquired and merged into AbbVie
  • 05 Aug 2016 Meda has been acquired by Mylan
  • 10 Oct 2014 Rottapharm Madaus has been acquired by Meda
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top